V Ratziu

Summary

Country: France

Publications

  1. ncbi request reprint Fat, diabetes, and liver injury in chronic hepatitis C
    Vlad Ratziu
    Service d Hepatogastroenterologie, Groupe Hospitalier Pitie Salpetriere, Paris, France
    Curr Gastroenterol Rep 6:22-9. 2004
  2. ncbi request reprint [Nonalcoholic steatohepatitis]
    V Ratziu
    Service d Hepato Gastroenterologie, Groupe Hospitalier Pitie Salpetriere, F 75651 Paris Cedex 13, France
    Ann Endocrinol (Paris) 66:1S71-80. 2005
  3. ncbi request reprint A prospective analysis of the prognostic value of biomarkers (FibroTest) in patients with chronic hepatitis C
    Yen Ngo
    Service d Hepato Gastroenterologie, Groupe Hospitalier Pitie Salpetriere, CNRS, Paris, France
    Clin Chem 52:1887-96. 2006
  4. doi request reprint A survey of patterns of practice and perception of NAFLD in a large sample of practicing gastroenterologists in France
    Vlad Ratziu
    Universite Pierre et Marie Curie, Assistance Publique Hopitaux de Paris, Hopital Pitie Salpetriere, Inserm UMR_S 938, France
    J Hepatol 57:376-83. 2012
  5. pmc A phase 2, randomized, double-blind, placebo-controlled study of GS-9450 in subjects with nonalcoholic steatohepatitis
    Vlad Ratziu
    Universite Pierre et Marie Curie, Hopital Pitie Salpetriere, Paris, France
    Hepatology 55:419-28. 2012
  6. pmc Applicability and precautions of use of liver injury biomarker FibroTest. A reappraisal at 7 years of age
    Thierry Poynard
    APHP UPMC Paris Liver Center, Paris, France
    BMC Gastroenterol 11:39. 2011
  7. pmc Meta-analyses of FibroTest diagnostic value in chronic liver disease
    Thierry Poynard
    Service d Hepato Gastroenterologie, Groupe Hospitalier Pitie Salpetriere, Universite Paris VI, CNRS ESA 8067 Paris, France
    BMC Gastroenterol 7:40. 2007
  8. pmc Diagnostic value of biochemical markers (NashTest) for the prediction of non alcoholo steato hepatitis in patients with non-alcoholic fatty liver disease
    Thierry Poynard
    Hepato Gastroenterology, AP HP Groupe Hospitalier Pitié Salpétrière, Paris, France
    BMC Gastroenterol 6:34. 2006
  9. pmc Prevalence of liver fibrosis and risk factors in a general population using non-invasive biomarkers (FibroTest)
    Thierry Poynard
    APHP UPMC Liver Center, Assistance Publique Hopitaux de Paris, Universite Pierre et Marie Curie, Paris, France
    BMC Gastroenterol 10:40. 2010
  10. doi request reprint Therapeutic trials in nonalcoholic steatohepatitis: insulin sensitizers and related methodological issues
    Vlad Ratziu
    Universite Pierre et Marie Curie, Assistance Publique Hopitaux de Paris, Hopital Pitie Salpetriere, INSERM UMRS 893 Paris, France
    Hepatology 52:2206-15. 2010

Collaborators

Detail Information

Publications100

  1. ncbi request reprint Fat, diabetes, and liver injury in chronic hepatitis C
    Vlad Ratziu
    Service d Hepatogastroenterologie, Groupe Hospitalier Pitie Salpetriere, Paris, France
    Curr Gastroenterol Rep 6:22-9. 2004
    ..Exciting new data are expanding our understanding of the mechanisms of steatogenesis in HCV infection and providing potential links between insulin resistance or hyperglycemic states and liver fibrogenesis...
  2. ncbi request reprint [Nonalcoholic steatohepatitis]
    V Ratziu
    Service d Hepato Gastroenterologie, Groupe Hospitalier Pitie Salpetriere, F 75651 Paris Cedex 13, France
    Ann Endocrinol (Paris) 66:1S71-80. 2005
    ..The encouraging results of the use of PPARgamma agonists and, in particular, rosiglitazone, in human or experimental models of NASH, justifies future large-scale, randomized controlled trials...
  3. ncbi request reprint A prospective analysis of the prognostic value of biomarkers (FibroTest) in patients with chronic hepatitis C
    Yen Ngo
    Service d Hepato Gastroenterologie, Groupe Hospitalier Pitie Salpetriere, CNRS, Paris, France
    Clin Chem 52:1887-96. 2006
    ..We compared the 5-year prognostic value of the FibroTest with biopsy staging for predicting cirrhosis decompensation and survival in patients with chronic HCV infection...
  4. doi request reprint A survey of patterns of practice and perception of NAFLD in a large sample of practicing gastroenterologists in France
    Vlad Ratziu
    Universite Pierre et Marie Curie, Assistance Publique Hopitaux de Paris, Hopital Pitie Salpetriere, Inserm UMR_S 938, France
    J Hepatol 57:376-83. 2012
    ..How this emerging entity is accepted and managed by a wider body of gastroenterologists is unknown, despite significant implications for the diagnosis of at-risk subjects and the utilization of healthcare resources...
  5. pmc A phase 2, randomized, double-blind, placebo-controlled study of GS-9450 in subjects with nonalcoholic steatohepatitis
    Vlad Ratziu
    Universite Pierre et Marie Curie, Hopital Pitie Salpetriere, Paris, France
    Hepatology 55:419-28. 2012
    ..5% to 17% across the GS-9450 treatment groups versus 35% in the placebo group...
  6. pmc Applicability and precautions of use of liver injury biomarker FibroTest. A reappraisal at 7 years of age
    Thierry Poynard
    APHP UPMC Paris Liver Center, Paris, France
    BMC Gastroenterol 11:39. 2011
    ..The aims were to estimate the prevalence of RFPN and of proven failures, and to identify factors associated with their occurrences...
  7. pmc Meta-analyses of FibroTest diagnostic value in chronic liver disease
    Thierry Poynard
    Service d Hepato Gastroenterologie, Groupe Hospitalier Pitie Salpetriere, Universite Paris VI, CNRS ESA 8067 Paris, France
    BMC Gastroenterol 7:40. 2007
    ....
  8. pmc Diagnostic value of biochemical markers (NashTest) for the prediction of non alcoholo steato hepatitis in patients with non-alcoholic fatty liver disease
    Thierry Poynard
    Hepato Gastroenterology, AP HP Groupe Hospitalier Pitié Salpétrière, Paris, France
    BMC Gastroenterol 6:34. 2006
    ..The aim was to develop and validate a new biomarker of non alcoholic steato hepatitis (NASH) the NashTest (NT) in patients with NAFLD...
  9. pmc Prevalence of liver fibrosis and risk factors in a general population using non-invasive biomarkers (FibroTest)
    Thierry Poynard
    APHP UPMC Liver Center, Assistance Publique Hopitaux de Paris, Universite Pierre et Marie Curie, Paris, France
    BMC Gastroenterol 10:40. 2010
    ..One challenge was to use them for estimating the prevalence of fibrosis, identifying independent risk factors and to propose screening strategies in the general population...
  10. doi request reprint Therapeutic trials in nonalcoholic steatohepatitis: insulin sensitizers and related methodological issues
    Vlad Ratziu
    Universite Pierre et Marie Curie, Assistance Publique Hopitaux de Paris, Hopital Pitie Salpetriere, INSERM UMRS 893 Paris, France
    Hepatology 52:2206-15. 2010
    ..It also highlights methodological challenges for trial design and proposes endpoints for future proof of principle, registrational, and postmarketing trials...
  11. doi request reprint A randomized controlled trial of high-dose ursodesoxycholic acid for nonalcoholic steatohepatitis
    Vlad Ratziu
    Universite Pierre et Marie Curie, Assistance Publique Hopitaux de Paris, Hopital Pitie Salpetriere, Inserm UMR_S 938, Paris, France
    J Hepatol 54:1011-9. 2011
    ..To date, no studies have assessed the efficacy and safety of high-dose UDCA (HD-UDCA) in patients with NASH...
  12. ncbi request reprint Can nonalcoholic steatohepatitis be diagnosed without liver biopsy?
    Vlad Ratziu
    Universite Pierre et Marie Curie, Assistance Publique Hopitaux de Paris, Hopital Pitie Salpetriere, INSERM UMRS_893, CdR Saint Antoine, Paris, France
    Biomark Med 3:353-61. 2009
    ..A noninvasive diagnosis of NASH would facilitate screening and monitoring of populations at risk, as well as the conduct of therapeutic trials...
  13. ncbi request reprint Pharmacologic therapy of non-alcoholic steatohepatitis
    Vlad Ratziu
    Universite Pierre et Marie Curie, Assistance Publique Hopitaux de Paris, Hopital Pitie Salpetriere, 47 83 Bd de l Hopital, Paris 75013, France
    Clin Liver Dis 13:667-88. 2009
    ..Therefore, there is an unmet medical need for the therapy of NASH. This article discusses this therapy, with particular emphasis on pharmacologic therapy...
  14. ncbi request reprint Fibrogenic impact of high serum glucose in chronic hepatitis C
    Vlad Ratziu
    Service d Hepatogastroenterologie, Hopital Pitie Salpetriere, 47 83 Bd de l Hopital, Paris 75013, France
    J Hepatol 39:1049-55. 2003
    ..We tested the hypothesis that high serum glucose and overweight might contribute to this variability...
  15. doi request reprint [Nonalcoholic fatty liver disease: 30 years research changed NASH]
    V Ratziu
    Inserm URM S 893, Service d Hepato gastro enterologie, Hopital Pitie Salpetriere, Assistance Publique Hopitaux de Paris, Universite Pierre et Marie Curie, 75651 Paris Cedex 13, France
    Gastroenterol Clin Biol 33:850-8. 2009
    ....
  16. doi request reprint Rosiglitazone for nonalcoholic steatohepatitis: one-year results of the randomized placebo-controlled Fatty Liver Improvement with Rosiglitazone Therapy (FLIRT) Trial
    Vlad Ratziu
    Universite Pierre et Marie Curie Paris VI, Assistance Publique Hopitaux de Paris, Service d Hepatogastroenterologie, Paris, France
    Gastroenterology 135:100-10. 2008
    ..Nonalcoholic steatohepatitis (NASH) is a liver disease that complicates insulin-resistant states. This trial tested the efficacy and safety of rosiglitazone, an insulin-sensitizing agent, in patients with NASH...
  17. pmc Diagnostic value of biochemical markers (FibroTest-FibroSURE) for the prediction of liver fibrosis in patients with non-alcoholic fatty liver disease
    Vlad Ratziu
    Hepato Gastroenterology, AP HP Groupe Hospitalier Pitié Salpétrière, Paris, France
    BMC Gastroenterol 6:6. 2006
    ..The aim of this study was to determine the diagnostic utility of non-invasive markers of fibrosis, validated in chronic viral hepatitis and alcoholic liver disease (FibroTest, FT), in patients with NAFLD...
  18. ncbi request reprint Review article: an unexpected virus-host interaction--the hepatitis C virus-diabetes link
    V Ratziu
    Service d Hepatogastroenterologie, Hopital Pitié Salpetriere and Université Pierre et Marie Curie, Paris, France
    Aliment Pharmacol Ther 22:56-60. 2005
    ..The consequences of the association between diabetes and HCV infection are an increased liver fibrosis stage and faster fibrosis progression rate. This article reviews recent human and experimental data on the HCV-diabetes association...
  19. ncbi request reprint Histological progression of non-alcoholic fatty liver disease: a critical reassessment based on liver sampling variability
    V Ratziu
    Université Pierre et Marie Curie and Assistance Publique, Hôpitaux de Pairs, Service d Hepatogastroenterologie, Groupe Hospitalier Pitie Salpetriere, Paris, France
    Aliment Pharmacol Ther 26:821-30. 2007
    ..In non-alcoholic fatty liver disease, histological lesions display a significant sampling variability that is ignored when interpreting histological progression during natural history or therapeutic interventions...
  20. ncbi request reprint Sampling variability of liver biopsy in nonalcoholic fatty liver disease
    Vlad Ratziu
    Service d Hepatogastroenterologie, Groupe Hospitalier Pitie Salpetriere, Paris, France
    Gastroenterology 128:1898-906. 2005
    ..The aim of this study was to assess the sampling error of liver biopsy and its impact on the diagnosis and staging of NASH...
  21. ncbi request reprint Survival, liver failure, and hepatocellular carcinoma in obesity-related cryptogenic cirrhosis
    Vlad Ratziu
    Service d Hepatogastroenterologie, Hopital Pitie Salpetriere, Paris, France
    Hepatology 35:1485-93. 2002
    ..Increased awareness of and better diagnostic strategies for nonalcoholic steatohepatitis in overweight patients are urgently needed...
  22. ncbi request reprint Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: a prospective study
    F Imbert-Bismut
    Department of Biochemistry, , Paris, France
    Lancet 357:1069-75. 2001
    ..60 to 1.00 (34% [115] of all patients). INTERPRETATION: A combination of basic serum markers could be used to substantially reduce the number of liver biopsies done in patients with chronic HCV infection...
  23. ncbi request reprint ActiTest accuracy for the assessment of histological activity grades in patients with chronic hepatitis C, an overview using Obuchowski measure
    T Poynard
    UPMC Paris Liver Center, AP HP, Paris, France
    Gastroenterol Clin Biol 34:388-96. 2010
    ..ActiTest (AT) is a biomarker of liver necro-inflammatory histological activity validated in patients with chronic hepatitis C (HCV)...
  24. doi request reprint Impact of interferon-alpha treatment on liver fibrosis in patients with chronic hepatitis B: an overview of published trials
    T Poynard
    Service d Hepatologie, UPMC Liver Center, hôpital La Pitié Salpêtrière, AP HP, 47 83, Boulevard de l Hopital, 75651 Paris Cedex 13, France
    Gastroenterol Clin Biol 33:916-22. 2009
    ..The present report is a review of the evidence-based data published so far...
  25. ncbi request reprint Effect of interferon therapy on the natural history of hepatitis C virus-related cirrhosis and hepatocellular carcinoma
    T Poynard
    Department of Medicine, University Paris VI, Paris, France
    Clin Liver Dis 3:869-81. 1999
    ..Although the number of randomized trials is [figure: see text] small, cumulative data suggest that IFN therapy can reduce the incidence of and the mortality from hepatocellular carcinoma in patients with cirrhosis...
  26. ncbi request reprint Screening for liver disease using non-invasive biomarkers (FibroTest, SteatoTest and NashTest) in patients with hyperlipidaemia
    V Ratziu
    APHP Hépatologie GHPS, Paris, France
    Aliment Pharmacol Ther 25:207-18. 2007
    ..It is impossible to perform liver biopsy in such a large number of hyperlipidaemic patients to identify patients with advanced liver fibrosis or with steatohepatitis (non-alcoholic steatohepatitis, NASH)...
  27. doi request reprint Methodological aspects of the interpretation of non-invasive biomarkers of liver fibrosis: a 2008 update
    T Poynard
    APHP Service d Hépato Gastroentérologie, Groupe Hospitalier Pitie Salpetriere, Universite Paris 6, CNRS ESA 8149 Paris, France
    Gastroenterol Clin Biol 32:8-21. 2008
    ....
  28. ncbi request reprint Biochemical markers of liver fibrosis: a comparison with historical features in patients with chronic hepatitis C
    Robert P Myers
    Department of Hepato Gastroenterology, hôpital La Pitié Salpêtrière, Paris, France
    Am J Gastroenterol 97:2419-25. 2002
    ..The aims of this study were: 1) to compare an index of five biochemical markers with historical features; and 2) to determine the utility of combining these features with the five-marker index for the prediction of significant fibrosis...
  29. ncbi request reprint Diagnostic value of serum protein profiling by SELDI-TOF ProteinChip compared with a biochemical marker, FibroTest, for the diagnosis of advanced fibrosis in patients with chronic hepatitis C
    R Morra
    UMR CNRS 8149, Pharmacy Faculty, Paris 5 University, Paris, and Biopredictive, Paris, France
    Aliment Pharmacol Ther 26:847-58. 2007
    ..FibroTest has been validated for the diagnosis of liver fibrosis in patients with chronic hepatitis C...
  30. ncbi request reprint Fibrosis in patients with chronic hepatitis C: detection and significance
    T Poynard
    Service d Hepato Gastroenterologie, Groupe Hospitalier Pitie Salpetriere, Paris, France
    Semin Liver Dis 20:47-55. 2000
    ..There is a major need for noninvasive markers of liver fibrosis. None are clearly useful today for the diagnosis of early stages of fibrosis...
  31. ncbi request reprint Natural history of HCV infection
    T Poynard
    Department of Internal Medicine, Groupe Hospitalier Pitie Salpetriere, Paris, France
    Baillieres Best Pract Res Clin Gastroenterol 14:211-28. 2000
    ..In contrast severe extrahepatic manifestations are rare, with 1% for systemic vasculitis...
  32. ncbi request reprint Fatigue in patients with chronic hepatitis C
    T Poynard
    Departments of Hepatogastroenterology, hôpital La Pitié Salpêtrière, Paris, France
    J Viral Hepat 9:295-303. 2002
    ..Hence, fatigue is the most frequent extrahepatic manifestation in patients infected with HCV. Fatigue is independently associated with female gender, age over 50 years, cirrhosis, depression and purpura...
  33. ncbi request reprint Serum biochemical markers accurately predict liver fibrosis in HIV and hepatitis C virus co-infected patients
    Robert P Myers
    Department of Hepatology and Gastroenterology, hôpital La Pitié Salpêtrière, Paris, France
    AIDS 17:721-5. 2003
    ..Our aim was to determine the operating characteristics of a non-invasive index of biochemical markers for the prediction of fibrosis in patients with HIV/HCV co-infection...
  34. ncbi request reprint A constellation of cardiovascular risk factors is associated with hepatic enzyme elevation in hyperlipidemic patients
    E Bruckert
    Department of Endocrinology, INSERM U 551 and IFR Caeur Muscle Vaisseau, Paris, France
    Metabolism 51:1071-6. 2002
    ..Because these abnormalities may not only be reversible but also associated with a poor prognosis, further studies are needed to identify those dyslipidemic patients who are at risk for the development of severe hepatic tissue damage...
  35. ncbi request reprint Rates and risk factors of liver fibrosis progression in patients with chronic hepatitis c
    T Poynard
    Service d Hepato Gastroenterologie, Groupe Hospitalier Pitie Salpetriere, Paris, France
    J Hepatol 34:730-9. 2001
    ..In hepatitis C there is controversy over the linearity of the rate of progression and the significance of gender, mode of infection and viral factors...
  36. ncbi request reprint Biochemical markers of liver fibrosis in patients infected by hepatitis C virus: longitudinal validation in a randomized trial
    T Poynard
    Hepatogastroenterology Groupe Hospitalier Pitié Salpêtrière, 47 Boulevard de l Hopital, 75651 Paris Cedex 13, France
    J Viral Hepat 9:128-33. 2002
    ..32 +/- 0.03 at 72 weeks; P=0.05). No significant differences were observed for hyaluronic acid.Hence, this fibrosis index could be used as a surrogate marker of the antifibrotic effect of treatments in patients with chronic hepatitis C...
  37. ncbi request reprint Hepatitis C in 6,865 patients 65 yr or older: a severe and neglected curable disease?
    Dominique Thabut
    Services d Hépato gastroentérologie, Group Hospitalier Pitié Salpêtrièe, Paris, France
    Am J Gastroenterol 101:1260-7. 2006
    ....
  38. ncbi request reprint Variability of the area under the receiver operating characteristic curves in the diagnostic evaluation of liver fibrosis markers: impact of biopsy length and fragmentation
    T Poynard
    APHP Groupe Hospitalier Pitié Salpétrière, Paris, France
    Aliment Pharmacol Ther 25:733-9. 2007
    ..Biopsy length and fragmentation are known as risk factors of false positive or false negative of biopsy but their quantitative impact on area under the receiver operating characteristic curve variability has not been assessed...
  39. ncbi request reprint Impact of adefovir dipivoxil on liver fibrosis and activity assessed with biochemical markers (FibroTest-ActiTest) in patients infected by hepatitis B virus
    T Poynard
    Pitie Salpetriere, Universite Paris, Paris, France
    J Viral Hepat 16:203-13. 2009
    ..62 to 0.25) (P < 0.0001). FibroTest-ActiTest provides a quantitative estimate of liver fibrosis and necroinflammatory activity in patients with chronic hepatitis B and may be an alternative to reduce the need for liver biopsy...
  40. ncbi request reprint Diagnostic and predictive factors of significant liver fibrosis and minimal lesions in patients with persistent unexplained elevated transaminases. A prospective multicenter study
    Victor de Ledinghen
    Service d Hepato Gastroenterologie, Hopital du Haut leveque, Pessac, France
    J Hepatol 45:592-9. 2006
    ..The aim of this prospective study was to identify diagnosis and clinical and biological factors associated with significant (bridging) fibrosis and minimal lesions of the liver in patients with persistent unexplained elevated ALT levels...
  41. ncbi request reprint FibroMAX: towards a new universal biomarker of liver disease?
    Rachel Morra
    Groupe Hospitalier Pitie Salpetriere, 47 83 boulevard de l Hopital, 75651 Paris Cedex 13, France
    Expert Rev Mol Diagn 7:481-90. 2007
    ..The possible causes of false-negative and false-positive results are also better identified. These tests, which are now available in 50 countries, can facilitate the screening and management of the most frequent liver diseases...
  42. ncbi request reprint Prediction of liver histological lesions with biochemical markers in patients with chronic hepatitis B
    Robert P Myers
    Department of Hepatology and Gastroenterology, Groupe Hospitalier Pitie Salpetriere, Paris, France
    J Hepatol 39:222-30. 2003
    ..Liver biopsy is the gold standard for assessing hepatitis B virus (HBV)-related histology. The aim was to determine the diagnostic utility of noninvasive serum markers in patients with chronic hepatitis B...
  43. ncbi request reprint Blood oxidative stress markers are unreliable markers of hepatic steatosis
    D Bonnefont-Rousselot
    Laboratoire des Lipides, Groupe Hosptalier Pitie Salpetriere AP HP, Paris, France
    Aliment Pharmacol Ther 23:91-8. 2006
    ..Non-alcoholic fatty liver disease (NAFLD) and viral hepatitis are associated with hepatic oxidative stress, which is partially dependent on the amount of hepatic fat...
  44. ncbi request reprint Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C in naive patients: 1999 update
    T Thevenot
    Service d Hepato Gastroenterologie, Groupe Hospitalier Pitie Salpetriere, Paris, France
    J Viral Hepat 8:48-62. 2001
    ..4%, P < 0.001). In conclusion, we confirm the dose and duration effect of IFN in chronic hepatitis C, and the efficacy of IFN-alpha in the treatment of acute hepatitis and in cirrhotic patients...
  45. doi request reprint Screening for liver fibrosis by using a noninvasive biomarker in patients with diabetes
    Sophie Jacqueminet
    Service de Diabetologie, APHP GHPS, Paris, France
    Clin Gastroenterol Hepatol 6:828-31. 2008
    ..We examined the efficacy of a screening strategy with a noninvasive fibrosis biomarker (FibroTest) in patients with diabetes...
  46. doi request reprint [Adherence to pegylated combination therapy in patients with chronic hepatitis C. Importance of the hepatologist, general practitioner, and nurse]
    C Wartelle-Bladou
    Service d Hepato Gastroenterologie, Centre Hospitalier du Pays d Aix, Avenue des Tamaris, 13616 Aix en Provence cedex 1, France
    Gastroenterol Clin Biol 32:S96-S108. 2008
    ....
  47. ncbi request reprint Appropriateness of liver biopsy
    T Poynard
    Groupe Hospitalier Pitie Salpetriere, Paris, France
    Can J Gastroenterol 14:543-8. 2000
    ..Therefore, further evaluation of the appropriateness of liver biopsy in the practical algorithm of such diseases is needed...
  48. ncbi request reprint Progression from isolated steatosis to steatohepatitis and fibrosis in nonalcoholic fatty liver disease
    R Pais
    Service d Hepatogastroenterologie, Hopital Pitie Salpetriere, Assistance Publique Hopitaux de Paris, Universite Pierre et Marie Curie, 47, Boulevard de l Hopital, 75013 Paris, France
    Clin Res Hepatol Gastroenterol 35:23-8. 2011
    ..If metabolic risk factors persist or deteriorate during follow-up and/or non-invasive markers suggest disease progression, a control liver biopsy should be considered...
  49. ncbi request reprint Biochemical markers of fibrosis in patients with chronic hepatitis C: a comparison with prothrombin time, platelet count, and age-platelet index
    Robert P Myers
    Department of Gastroenterology and Hepatology, Groupe Hospitalier Pitie Salpetriere, Paris, France
    Dig Dis Sci 48:146-53. 2003
    ..In conclusion, an index of five biochemical markers accurately predicts significant hepatitis C-related fibrosis and is superior to traditional markers...
  50. ncbi request reprint Noninvasive biomarkers for the screening of fibrosis, steatosis and steatohepatitis in patients with metabolic risk factors: FibroTest-FibroMax experience
    Mona Munteanu
    Biopredictive, and Groupe Hospitalier Pitié Salpêtrière, 47 83 boulevard de l Hopital, Paris, France
    J Gastrointestin Liver Dis 17:187-91. 2008
  51. ncbi request reprint [Treatment and prevention of hepatitis C]
    T Poynard
    Service d hépato gastro entérologie Groupe hospitalier Pitié La Salpêtrière, Paris
    Rev Prat 50:1100-7. 2000
    ..Treatment of HCV should be systematically discussed in patients coinfected with HIV and HCV...
  52. ncbi request reprint Expression of connective tissue growth factor in experimental rat and human liver fibrosis
    V Paradis
    Service d Anatomie Pathologique, Hopital de Bicetre, Le Kremlin Bicetre, France
    Hepatology 30:968-76. 1999
    ..In conclusion, this study shows that CTGF is strongly expressed during liver fibrogenesis, and hepatic stellate cells seem to be the major cellular sources of CTGF in the liver...
  53. ncbi request reprint [Can metabolic steatohepatitis be treated?]
    Vlad Ratziu
    Groupe Hospitalier Pitié Salpêtrière et Université Pierre et Marie Curie, Paris
    Gastroenterol Clin Biol 31:333-40. 2007
  54. doi request reprint Facial cosmetic filler injections as possible target for systemic sarcoidosis in patients treated with interferon for chronic hepatitis C: two cases
    Vincent Descamps
    Department of Dermatology, Bichat Claude Bernard Hospital, Paris, France
    Dermatology 217:81-4. 2008
    ..Cosmetic filler injections are now a very common procedure for aesthetic purposes. Today no contra-indication is given anymore to any patient for an intradermal filling...
  55. doi request reprint Biomarkers of liver injury for hepatitis clinical trials: a meta-analysis of longitudinal studies
    Thierry Poynard
    University Pierre and Marie Curie Liver Center, Paris, France
    Antivir Ther 15:617-31. 2010
    ..We aimed to review evidence-based published data of biomarkers that have been validated as non-invasive alternatives to biopsy as end points for HBV and HCV infection trials...
  56. ncbi request reprint Biomarkers of liver fibrosis
    Thierry Poynard
    Service d Hepato Gastroenterologie, Groupe Hospitalier Pitie Salpetriere, Universite Paris VI, CNRS ESA 8067 Paris, France
    Adv Clin Chem 46:131-60. 2008
    ..Neither biomarkers nor biopsy are sufficient alone to take definitive decision in a given patient and all the clinical and biological data must be taken into account...
  57. pmc Concordance in a world without a gold standard: a new non-invasive methodology for improving accuracy of fibrosis markers
    Thierry Poynard
    APHP Groupe Hospitalier Pitié Salpétrière, Universite Paris VI, CNRS UMR, Paris, France
    PLoS ONE 3:e3857. 2008
    ..The aim was to identify factors associated with LSM accuracy using FT as a non-invasive endpoint and vice versa...
  58. pmc Hirsch index and truth survival in clinical research
    Thierry Poynard
    University Pierre et Marie Curie Assistance Publique Hôpitaux de Paris Liver Center, Service d Hepato Gastroenterologie, Groupe Hospitalier Pitie Salpetriere, Paris, France
    PLoS ONE 5:e12044. 2010
    ..We hypothesized that publications with a first author having a higher Hirsch' index value (h-I), which quantifies and predicts an individual's scientific research output, should have a longer half-life...
  59. ncbi request reprint Standardization of ROC curve areas for diagnostic evaluation of liver fibrosis markers based on prevalences of fibrosis stages
    Thierry Poynard
    Assistance Publique Hôpitaux de Paris Groupe Hospitalier Pitié Salpêtrière, Paris, France
    Clin Chem 53:1615-22. 2007
    ..The aim of this study was to assess the relationships between the AUC and the prevalence of each fibrosis stage and to elaborate simple methods of standardization...
  60. ncbi request reprint Viral hepatitis C
    Thierry Poynard
    Service d Hepato gastro enterologie, Groupe Hospitalier Pitie Salpetriere, Universite, Paris, France
    Lancet 362:2095-100. 2003
    ..These antiviral treatments reduce liver fibrosis progression and can reverse cirrhosis. Unfortunately, even in developed countries, death due to hepatitis C is increasing because of inadequate detection and treatment...
  61. ncbi request reprint FibroTest-FibroSURE: towards a universal biomarker of liver fibrosis?
    Thierry Poynard
    Groupe Hospitalier Pitie Salpetriere, 47 83 boulevard de l Hopital, 75651 Paris Cedex 13, France
    Expert Rev Mol Diagn 5:15-21. 2005
    ..The possible causes of false negatives and positives are also better identified. These tests, which are now available in 12 countries, can facilitate the screening and management of the most frequent liver diseases...
  62. ncbi request reprint A comparison of fibrosis progression in chronic liver diseases
    Thierry Poynard
    Service d Hepato Gastroenterologie, Groupe Hospitalier Pitie Salpetriere, et UPRESA 8067 CNRS, 47 83 boulevard de l Hopital, 75651 Paris Cedex 13, France
    J Hepatol 38:257-65. 2003
    ..No study has compared the liver fibrosis progression rates among chronic liver diseases and the risk factors in order to better organize screening strategies...
  63. ncbi request reprint Effect of treatment with peginterferon or interferon alfa-2b and ribavirin on steatosis in patients infected with hepatitis C
    Thierry Poynard
    Service d Hepato Gastroenterologie, Groupe Hospitalier Pitie Salpetriere, Universite Paris VI, Paris, France
    Hepatology 38:75-85. 2003
    ..In conclusion, sustained disappearance of the virus is associated with reduction of steatosis in genotype 3 as well as a correction of baseline low serum cholesterol...
  64. ncbi request reprint Truth survival in clinical research: an evidence-based requiem?
    Thierry Poynard
    Service d Hepato Gastroenterologie, Groupe Hospitalier Pitie Salpetriere, 47 83 boulevard de l Hopital, 75651 Paris Cedex 13, France
    Ann Intern Med 136:888-95. 2002
    ..Factors associated with the survival of truth of clinical conclusions in the medical literature are unknown. The authors hypothesized that conclusions derived from studies using better methodology should have a longer half-life...
  65. ncbi request reprint Prospective analysis of discordant results between biochemical markers and biopsy in patients with chronic hepatitis C
    Thierry Poynard
    Service d Hepato Gastroenterologie, Groupe Hospitalier Pitie Salpetriere, Universite Paris VI, Paris, France
    Clin Chem 50:1344-55. 2004
    ....
  66. doi request reprint [Hepatotoxicity of metastatic colorectal cancer chemotherapy: systematic review]
    I Baumgaertner
    Service d Hepatogastroenterologie, Hopital Pitie Salpetriere, 75013 Paris, France
    Bull Cancer 97:559-69. 2010
    ..Data concerning these hepatic lesions and outcome after surgery are resumed in this review...
  67. doi request reprint Long-term efficacy of rosiglitazone in nonalcoholic steatohepatitis: results of the fatty liver improvement by rosiglitazone therapy (FLIRT 2) extension trial
    Vlad Ratziu
    Hopital Pitie Salpetriere, Service d Hepatogastroenterologie, Universite Pierre et Marie Curie Paris VI, Assistance Publique Hopitaux de Paris, France
    Hepatology 51:445-53. 2010
    ..Likewise, there was no improvement in the NAS score, ballooning, intralobular inflammation, fibrosis stage, or area of fibrosis with 2 additional years of RSG in the RSG-RSG group...
  68. doi request reprint Serum adipokine levels predictive of liver injury in non-alcoholic fatty liver disease
    Maud Lemoine
    Faculte de Medecine, Universite Pierre et Marie Curie, Paris, France
    Liver Int 29:1431-8. 2009
    ....
  69. ncbi request reprint Impact of treatment on extra hepatic manifestations in patients with chronic hepatitis C
    Patrice Cacoub
    Department of Internal Medicine, hôpital La Pitié Salpêtrière, 83 Boulevard de l hopital, 75651 Paris Cedex 13, France
    J Hepatol 36:812-8. 2002
    ..The aim was to assess the prevalence of these symptoms prior to any treatment, and on prolonged follow-up in treated and untreated patients...
  70. ncbi request reprint Longitudinal assessment of histology surrogate markers (FibroTest-ActiTest) during lamivudine therapy in patients with chronic hepatitis B infection
    Thierry Poynard
    Department of Hepatology and Gastroenterology, Groupe Hospitalier Pitie Salpetriere, Paris, France
    Am J Gastroenterol 100:1970-80. 2005
    ..The aim was to use these markers in a prospective study of patients treated with lamivudine in order to assess the impact of treatment, as well as the factors associated with fibrosis progression...
  71. ncbi request reprint Natural history and predictors of disease severity in chronic hepatitis C
    Julien Massard
    Service d Hepato Gastroenterologie, Groupe Hospitalier Pitie Salpetriere, 47 Boulevard de l Hopital, 75651 Paris Cedex 13, France
    J Hepatol 44:S19-24. 2006
    ..The recent validation of non-invasive biomarkers should facilitate the study of fibrosis progression in large populations...
  72. ncbi request reprint Non-invasive detection of liver fibrosis: Is superparamagnetic iron oxide particle-enhanced MR imaging a contributive technique?
    Olivier Lucidarme
    Department of Radiology, Universite Paris VI, Hôpital de la Pitié Salpêtrière Assistance Publique Hôpitaux de Paris, 47, Boulevard de l Hopital, 75651 Paris Cedex 13, France
    Eur Radiol 13:467-74. 2003
    ..In patients with chronic liver diseases, SPIO-enhanced MR imaging exhibits non-tumor hypersignal intensities indicative of liver fibrosis by decreasing the signal from the non-fibrotic areas where Kupffer cells are present...
  73. ncbi request reprint FAS promoter polymorphisms correlate with activity grade in hepatitis C patients
    Dorian McIlroy
    Laboratoire d Immunologie Cellulaire et Tissulaire bService de Gastroentérologie, Hopital Pitie Salpetriere, Paris, France
    Eur J Gastroenterol Hepatol 17:1081-8. 2005
    ..Hepatocytes are susceptible to FAS-mediated apoptosis. The impact of polymorphisms in the FAS gene on histopathological features of HCV infection was therefore investigated...
  74. ncbi request reprint Portal lymphocytic infiltrate in alcoholic liver disease
    Magali Colombat
    Service Central d Anatomie Pathologique, Groupe Hospitalier Pitie Salpetriere, Paris, France
    Hum Pathol 33:1170-4. 2002
    ..These results suggest that lymphocytes may play a role in the pathogenesis of alcohol-induced liver fibrosis...
  75. doi request reprint A comparison of the fibrotic potential of nonalcoholic fatty liver disease and chronic hepatitis C
    Frederic Charlotte
    Universite Pierre et Marie Curie, Paris VI, Assistance Publique Hopitaux de Paris, Hopital Pitie Salpetriere, Service d Anatomie Pathologique
    Hum Pathol 41:1178-85. 2010
    ..The fibrotic potential of nonalcoholic fatty liver disease is as severe as that of chronic hepatitis C virus...
  76. ncbi request reprint Continuous infusion of high-dose omeprazole is more effective than standard-dose omeprazole in patients with high-risk peptic ulcer bleeding: a retrospective study
    M Simon-Rudler
    Service d hépatologie et de gastroentérologie, hôpital Pitié Salpêtrière AP HP, Paris, France
    Aliment Pharmacol Ther 25:949-54. 2007
    ..High-dose omeprazole reduces the rate of recurrent bleeding after endoscopic treatment of peptic ulcer bleeding. However, the effectiveness of high-dose vs. standard-dose omeprazole in peptic ulcer bleeding has never been shown...
  77. pmc An accurate definition of the status of inactive hepatitis B virus carrier by a combination of biomarkers (FibroTest-ActiTest) and viral load
    Yen Ngo
    Service d Hepato Gastroenterologie, Groupe Hospitalier Pitie Salpetriere, Universite Paris VI, CNRS UMR 8149, Paris, France
    PLoS ONE 3:e2573. 2008
    ..We compared the 4-year prognostic value of combining FT-AT and viral load for a better definition of the inactive carrier status...
  78. doi request reprint The diagnostic value of combining carbohydrate-deficient transferrin, fibrosis, and steatosis biomarkers for the prediction of excessive alcohol consumption
    Francoise Imbert-Bismut
    Department of Biochemistry, APHP Groupe Hospitalier Pitié Salpétrière, Paris, France
    Eur J Gastroenterol Hepatol 21:18-27. 2009
    ..The aim was to improve the accuracy of the percentage of CDT by taking into account the presence of fibrosis and steatosis, estimated using biomarkers FibroTest and SteatoTest...
  79. ncbi request reprint An overview of nonalcoholic steatohepatitis: past, present and future directions
    Alina Pascale
    Universite Pierre et Marie Curie, Assistance Publique Hopitaux de Paris, Hopital Pitie Salpetriere, Paris, France
    J Gastrointestin Liver Dis 19:415-23. 2010
    ....
  80. ncbi request reprint Diagnostic value of FibroTest with normal serum aminotransferases
    Thierry Poynard
    Hepatology 43:374-5; author reply 375-6. 2006
  81. ncbi request reprint [Hepatocellular carcinoma and non alcoholic steatohepatitis: are we looking at the tip of the iceberg?]
    Vlad Ratziu
    Service Hepatogastroenterologie, Hopital Pitie Salpetriere, Paris
    Gastroenterol Clin Biol 27:869-75. 2003
  82. ncbi request reprint [What are the indications for treatment of acute hepatitis C?]
    Robert P Myers
    Service d Hepato Gastroenterologie, Groupe Hospitalier Pitie Salpetriere, Paris
    Gastroenterol Clin Biol 26:B188-93. 2002
  83. ncbi request reprint Viral hepatitis B
    Ching Lung Lai
    Department of Medicine, University of Hong Kong, Queen Mary Hospital, Hong Kong, People s Republic of China
    Lancet 362:2089-94. 2003
    ..Lamivudine, and presumably other nucleoside analogues, can reverse cirrhosis of the liver...
  84. ncbi request reprint The predictive value of Fibrotest vs. APRI for the diagnosis of fibrosis in chronic hepatitis C
    Sophie Le Calvez
    Hepatology 39:862-3; author reply 863. 2004
  85. ncbi request reprint Biomarkers for the prediction of liver fibrosis in patients with chronic alcoholic liver disease
    Sylvie Naveau
    Department of Hepato Gastroenterology, Hopital Antoine Beclere, Clamart, France
    Clin Gastroenterol Hepatol 3:167-74. 2005
    ..The aim of this study was to determine the diagnostic use of noninvasive markers of fibrosis in patients with chronic alcoholic liver disease...
  86. ncbi request reprint Letter regarding article by Ruttmann et al, "gamma-Glutamyltransferase as a risk factor for cardiovascular disease mortality: an epidemiological investigation in a cohort of 163,944 Austrian adults"
    Philippe Giral
    Circulation 113:e299; author reply e299-300. 2006
  87. ncbi request reprint FibroTest has better diagnostic and prognostic values than the aspartate aminotransferase-to-platelet ratio index in patients with chronic hepatitis C
    Rachel Morra
    Hepatology 47:353-4; author reply 354-6. 2008
  88. doi request reprint Reproducibility of non-invasive fibrosis biomarkers, FibroMeter and FibroTest, could be improved by respecting the analytical standardizations
    Mona Munteanu
    Clin Biochem 41:1113-4. 2008
  89. ncbi request reprint Assessing the outcome of nonalcoholic steatohepatitis? It's time to get serious
    Vlad Ratziu
    Hepatology 44:802-5. 2006
  90. ncbi request reprint Biomarkers as a first-line estimate of injury in chronic liver diseases: time for a moratorium on liver biopsy?
    Thierry Poynard
    Gastroenterology 128:1146-8; author reply 1148. 2005
  91. ncbi request reprint Age and gender will survive to competing risks as fibrosis factors
    Thierry Poynard
    Gastroenterology 128:519-20; author reply 520-1. 2005
  92. ncbi request reprint [Pre-C mutations of the HBV]
    Vlad Ratziu
    Service Hépato gastroentérologie, Hopital Pitie Salpetriere, 47, Boulevard de l Hopital, 75651 Paris Cedex, France
    Gastroenterol Clin Biol 26:509-13. 2002
  93. ncbi request reprint The diagnostic value of biomarkers (AshTest) for the prediction of alcoholic steato-hepatitis in patients with chronic alcoholic liver disease
    Dominique Thabut
    Department of Hepato Gastroenterology, Groupe Hospitalier Pitie Salpetriere, 47 83 boulevard de l Hopital, 75651 CNRS UMR 8149, Paris Cedex 13, France
    J Hepatol 44:1175-85. 2006
    ..The aim was to identify a panel of biomarkers (AshTest) for the diagnosis of alcoholic steato-hepatitis (ASH), in patients with chronic alcoholic liver disease...
  94. ncbi request reprint Discussion on celiac disease in patients with severe liver disease: gluten-free diet may reverse hepatic failure
    Vlad Ratziu
    Gastroenterology 123:2158-9; author reply 2159-60. 2002
  95. ncbi request reprint The elusiveness of "normal" ALT in fatty liver
    Vlad Ratziu
    Hepatology 39:1172; author reply 1173. 2004
  96. ncbi request reprint NASH: a hidden and silent fibroser finally revealed?
    Vlad Ratziu
    J Hepatol 42:12-4. 2005
  97. ncbi request reprint Hepatitis C infection and proteinuria
    Hassane Izzedine
    Kidney Int 68:2402. 2005
  98. ncbi request reprint Anti-tumor necrosis factor-alpha therapy in severe alcoholic hepatitis: are large randomized trials still possible?
    Thierry Poynard
    J Hepatol 38:518-20. 2003
  99. ncbi request reprint [Non-alcoholic steatosis: limits of current knowledge and lessons for hepatologists]
    Vlad Ratziu
    Gastroenterol Clin Biol 27:715-7. 2003